FDA seeks information on Biopure's blood substitute:
This article was originally published in Clinica
Executive Summary
The US FDA has completed its review of Biopure's blood substitute marketing application and has onlyasked for more information on the clinical trial data. No new studies of the product, called Hemopure, have been requested. Following the announcement on Friday, August 1, shares in the Cambridge, Massachusetts firm shot up by 22%. The FDA's response comes one month in advance of the August 29 deadline it had set (see Clinica No 1060, p 18) for ruling on the use of Hemopure as a treatment for acutely anaemic patients undergoing orthopaedic surgery.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.